VPIM
ALXN

Vanguard Personalized Indexing Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,800
Closed -$882K – 1075
2021
Q2 		$882K Buy
4,800
+2,227
+87% +$382K 0.09% 248
2021
Q1 		$393K Buy
2,573
+1,125
+78% +$174K 0.06% 402
2020
Q4 		$226K Buy
+1,448
New +$186K 0.05% 464

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Vanguard Personalized Indexing Management's ALXN Position: Q3 2021 in Review

Vanguard Personalized Indexing Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,800 shares — an estimated $882K sold.

Vanguard Personalized Indexing Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $882K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Vanguard Personalized Indexing Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 4,800 Alexion Pharmaceuticals shares in Q3 2021, an estimated $882K.
  • Vanguard Personalized Indexing Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Vanguard Personalized Indexing Management's Alexion Pharmaceuticals position peaked at $882K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vanguard Personalized Indexing Management's 13F filing for Q3 2021, filed 9 Nov 2021.